{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:22Z","timestamp":1771272142692,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03452-9","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:14:59Z","timestamp":1766394899000},"page":"537-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?"],"prefix":"10.1007","volume":"43","author":[{"given":"Chara","family":"Tsiampali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iordanis","family":"Vagiakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysanthi","family":"Sardeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios G.","family":"Konstas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"3452_CR1","doi-asserted-by":"publisher","first-page":"1015338","DOI":"10.3389\/fphar.2022.1015338","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13:1015338.","journal-title":"Front Pharmacol"},{"key":"3452_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","volume":"109","author":"M Pazos","year":"2025","unstructured":"Pazos M, Traverso CE, Viswanathan A. European Glaucoma Society terminology and guidelines for glaucoma, 6th edition. Br J Ophthalmol. 2025;109:1\u2013212.","journal-title":"Br J Ophthalmol"},{"key":"3452_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101303","volume":"103","author":"SG Asrani","year":"2024","unstructured":"Asrani SG, McGlumphy E, Al-Aswad LA, Chaya CJ, Lin S, Musch DC, et al. The relationship between intraocular pressure and glaucoma: an evolving concept. Prog Retin Eye Res. 2024;103:101303.","journal-title":"Prog Retin Eye Res"},{"key":"3452_CR4","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.4103\/IJO.IJO_2706_22","volume":"71","author":"S Subbulakshmi","year":"2023","unstructured":"Subbulakshmi S, Kavitha S, Venkatesh R. Prostaglandin analogs in ophthalmology. Indian J Ophthalmol. 2023;71:1768\u201376.","journal-title":"Indian J Ophthalmol"},{"key":"3452_CR5","first-page":"741","volume":"4","author":"AJ Lee","year":"2010","unstructured":"Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741\u201364.","journal-title":"Clin Ophthalmol"},{"key":"3452_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ceo.13989","volume":"50","author":"RJ Casson","year":"2022","unstructured":"Casson RJ. Medical therapy for glaucoma: a review. Clin Exp Ophthalmol. 2022;50:198\u2013212.","journal-title":"Clin Exp Ophthalmol"},{"key":"3452_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/bs.pbr.2015.06.010","volume":"221","author":"AGP Konstas","year":"2015","unstructured":"Konstas AGP, Katsanos A, Quaranta L, Mikropoulos DG, Tranos PG, Teus MA. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015;221:297\u2013318.","journal-title":"Prog Brain Res"},{"key":"3452_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. Ophthalmology. 2016;123:129\u201340.","journal-title":"Ophthalmology"},{"key":"3452_CR9","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53:S57-68.","journal-title":"Surv Ophthalmol"},{"key":"3452_CR10","unstructured":"Tripathy K, Patel P, Geetha R. Latanoprost. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [Cited: 2025 June 17]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK540978\/. Accessed June 17, 2025."},{"key":"3452_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2023.102424","volume":"74","author":"B Benitez","year":"2024","unstructured":"Benitez B, Anter AM, Arcuri J, Bhattacharya SK. Currently available prostanoids for the treatment of glaucoma and ocular hypertension: a review. Curr Opin Pharmacol. 2024;74:102424.","journal-title":"Curr Opin Pharmacol"},{"key":"3452_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/DDDT.S506520","volume":"19","author":"I Vagiakis","year":"2025","unstructured":"Vagiakis I, Papadopoulou E, Amaxilati E, Tsiropoulos G, Konstas AG, Panos G. Bimatoprost intracameral implant (Durysta\u00ae): a new era in glaucoma management through sustained-release innovation. Drug Des Dev Ther. 2025;19:703\u201314.","journal-title":"Drug Des Dev Ther"},{"key":"3452_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","volume":"17","author":"F Aptel","year":"2008","unstructured":"Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667\u201373.","journal-title":"J Glaucoma"},{"key":"3452_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/eye.2014.114","volume":"28","author":"AJ Connor","year":"2014","unstructured":"Connor AJ, Fraser SG. Glaucoma prescribing trends in England 2000 to 2012. Eye. 2014;28:863\u20139.","journal-title":"Eye"},{"key":"3452_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060956","volume":"12","author":"M Tanito","year":"2022","unstructured":"Tanito M. Nation-wide analysis of glaucoma medication prescription in fiscal year of 2019 in Japan. J Pers Med. 2022;12:956.","journal-title":"J Pers Med"},{"key":"3452_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227595","volume":"15","author":"L Yu","year":"2020","unstructured":"Yu L, Ding K, Luo L, Yu Z. Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLoS ONE. 2020;15:e0227595.","journal-title":"PLoS ONE"},{"key":"3452_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1120672117747030","volume":"28","author":"A Diagourtas","year":"2018","unstructured":"Diagourtas A, Kagelaris K, Oikonomakis K, Droulias A, Kokolakis N, Papaconstantinou D. Prospective study comparing Xalatan\u00ae eye drops and two similar generics as to the efficacy and safety profile. Eur J Ophthalmol. 2018;28:378\u201384.","journal-title":"Eur J Ophthalmol"},{"key":"3452_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00347-014-3097-x","volume":"112","author":"MA Leitritz","year":"2015","unstructured":"Leitritz MA, Lipp H-P, Voykov B, Ziemssen F. Originalpr\u00e4parat versus Generika\u2014Latanoprost: Wie gleich ist unterschiedlich? Ophthalmologe. 2015;112:127\u201339.","journal-title":"Ophthalmologe"},{"key":"3452_CR19","unstructured":"Galinos. Active substance\u2014Latanoprost\u2014Marketing [Internet]. [cited 2025 Jun 25]. https:\/\/www.galinos.gr\/web\/drugs\/main\/substances\/latanoprost\/marketing. Accessed June 25, 2025."},{"key":"3452_CR20","unstructured":"US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) [Internet]. Silver Spring (MD): US Food and Drug Administration; [cited 2025 Jun 19]. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book. Accessed June 19, 2025."},{"key":"3452_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2015.11.021","volume":"163","author":"JH Queen","year":"2016","unstructured":"Queen JH, Feldman RM, Lee DA. Variation in number of doses, bottle volume, and calculated yearly cost of generic and branded latanoprost for glaucoma. Am J Ophthalmol. 2016;163:70\u20134.","journal-title":"Am J Ophthalmol"},{"key":"3452_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ophtha.2014.11.022","volume":"122","author":"JD Stein","year":"2015","unstructured":"Stein JD, Shekhawat N, Talwar N, Balkrishnan R. Impact of the introduction of generic latanoprost on glaucoma medication adherence. Ophthalmology. 2015;122:738\u201347.","journal-title":"Ophthalmology"},{"key":"3452_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122209","volume":"627","author":"J Renukuntla","year":"2022","unstructured":"Renukuntla J, Palakurthi SS, Bolla PK, Clark BA, Boddu SHS, Manda P, et al. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products. Int J Pharm. 2022;627:122209.","journal-title":"Int J Pharm"},{"key":"3452_CR24","volume":"7","author":"AJ Tatham","year":"2020","unstructured":"Tatham AJ. The use of generic medications for glaucoma. J Ophthalmol. 2020;7:1651265.","journal-title":"J Ophthalmol"},{"key":"3452_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.22336\/rjo.2020.41","volume":"64","author":"S Bhartiya","year":"2020","unstructured":"Bhartiya S, Dhingra D. Generics versus brand-named drugs for glaucoma: the debate continues. Rom J Ophthalmol. 2020;64:239\u201344.","journal-title":"Rom J Ophthalmol"},{"key":"3452_CR26","unstructured":"FDA. Draft guidance on latanoprost [Internet]. Draft guidance on latanoprost. US Food and Drug Administration; 2018 [cited 2025 Jul 19]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Latanoprost_draft_Ophthalmic%20solution_RLD%2020597_RC07-18.pdf. Accessed June 19, 2025."},{"key":"3452_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9394(99)00073-2","volume":"128","author":"AGP Konstas","year":"1999","unstructured":"Konstas AGP, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999;128:15\u201320.","journal-title":"Am J Ophthalmol"},{"key":"3452_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sj\u00f6quist","year":"2002","unstructured":"Sj\u00f6quist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:6\u201312.","journal-title":"Surv Ophthalmol"},{"key":"3452_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology. 1996;103:138\u201347.","journal-title":"Ophthalmology"},{"key":"3452_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","volume":"103","author":"P Watson","year":"1996","unstructured":"Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126\u201337.","journal-title":"Ophthalmology"},{"key":"3452_CR31","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB, Alm A, Watson P, Stjernschantz J, Aasved H, Jangard P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Ophthalmology. 1996;103:1916\u201324.","journal-title":"Ophthalmology"},{"key":"3452_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/bjo.85.8.983","volume":"85","author":"WY Zhang","year":"2001","unstructured":"Zhang WY. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85:983\u201390.","journal-title":"Br J Ophthalmol"},{"key":"3452_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","volume":"112","author":"AGP Konstas","year":"2005","unstructured":"Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262\u20136.","journal-title":"Ophthalmology"},{"key":"3452_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ophtha.2006.07.064","volume":"114","author":"AGP Konstas","year":"2007","unstructured":"Konstas AGP, Kozobolis VP, Katsimpris IE, Boboridis K, Koukoula S, Jenkins JN, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653\u20137.","journal-title":"Ophthalmology"},{"key":"3452_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/IJG.0b013e318259b47c","volume":"22","author":"M Digiuni","year":"2013","unstructured":"Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. J Glaucoma. 2013;22:707\u201312.","journal-title":"J Glaucoma"},{"key":"3452_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ogla.2019.10.002","volume":"3","author":"AT Steensberg","year":"2019","unstructured":"Steensberg AT, M\u00fcllertz OO, Virgili G, Azuara-Blanco A, Kolko M. Evaluation of generic versus original prostaglandin analogues in the treatment of glaucoma. Ophthalmol Glaucoma. 2019;3:51\u20139.","journal-title":"Ophthalmol Glaucoma"},{"key":"3452_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0301-4738.30707","volume":"55","author":"A Narayanaswamy","year":"2007","unstructured":"Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan\u00ae in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55:127\u201331.","journal-title":"Indian J Ophthalmol"},{"key":"3452_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/aos.12321","volume":"92","author":"P Egan","year":"2014","unstructured":"Egan P, Harris A, Siesky B, Abrams\u2010Tobe L, Gerber AL, Park J, et al. Comparison of intraocular pressure in glaucoma subjects treated with Xalatan\u00ae versus generic latanoprost. Acta Ophthalmol. 2014;92:217\u20138.","journal-title":"Acta Ophthalmol"},{"key":"3452_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/1440-1681.12329","volume":"42","author":"S Golan","year":"2015","unstructured":"Golan S, Rosenfeld E, Shemesh G, Kurtz S. Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clin Exp Pharmacol Physiol. 2015;42:220\u20134.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"3452_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09286586.2018.1516786","volume":"26","author":"DH Kim","year":"2019","unstructured":"Kim DH, Addis VM, Pan W, VanderBeek BL. Comparative effectiveness of generic latanoprost versus branded prostaglandin analogs for primary open angle glaucoma. Ophthalmic Epidemiol. 2019;26:63\u201371.","journal-title":"Ophthalmic Epidemiol"},{"key":"3452_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/jop.2013.0174","volume":"30","author":"CA Rasmussen","year":"2014","unstructured":"Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther. 2014;30:163\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3452_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40265-017-0843-9","volume":"78","author":"G Holl\u00f3","year":"2018","unstructured":"Holl\u00f3 G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin\/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39\u201364.","journal-title":"Drugs"},{"key":"3452_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"3452_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00061198-200106000-00017","volume":"10","author":"DC Broadway","year":"2001","unstructured":"Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva: J glaucoma. J Glaucoma. 2001;10:237\u201349.","journal-title":"J Glaucoma"},{"key":"3452_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OPTH.S24983","volume":"5","author":"MT Gado","year":"2011","unstructured":"Gado MT. First experience with BAK-free travoprost 0.004% in topical glaucoma medication. Clin Ophthalmol. 2011;5:1\u20135.","journal-title":"Clin Ophthalmol"},{"key":"3452_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14740338.2021.1873947","volume":"20","author":"AG Konstas","year":"2021","unstructured":"Konstas AG, Labb\u00e9 A, Katsanos A, Meier-Gibbons F, Irkec M, Boboridis KG, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021;20:453\u201366.","journal-title":"Expert Opin Drug Saf"},{"key":"3452_CR47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","volume":"979","author":"J-F Rouland","year":"2013","unstructured":"Rouland J-F, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;979:196\u2013200.","journal-title":"Br J Ophthalmol"},{"key":"3452_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/02713683.2011.631722","volume":"37","author":"MY Kahook","year":"2012","unstructured":"Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res. 2012;37:101\u20138.","journal-title":"Curr Eye Res"},{"key":"3452_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jcjo.2016.05.014","volume":"51","author":"N Hallaji NAE","year":"2016","unstructured":"Hallaji NAE N, Rao PPN P, Trope GE GE. Preservative content in generic and brand name glaucoma eye drops. Can J Ophthalmol. 2016;51:492\u20136.","journal-title":"Can J Ophthalmol"},{"key":"3452_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10792-016-0280-x","volume":"37","author":"D Angmo","year":"2017","unstructured":"Angmo D, Wadhwani M, Velpandian T, Kotnala A, Sihota R, Dada T. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations. Int Ophthalmol. 2017;37:423\u20138.","journal-title":"Int Ophthalmol"},{"key":"3452_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/aos.13355","volume":"95","author":"M Kolko","year":"2017","unstructured":"Kolko M, Koch Jensen P. The physical properties of generic latanoprost ophthalmic solutions are not identical. Acta Ophthalmol. 2017;95:370\u20133.","journal-title":"Acta Ophthalmol"},{"key":"3452_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1167\/iovs.04-1367","volume":"47","author":"R Varma","year":"2006","unstructured":"Varma R, Winarko J, Kiat-Winarko T, Winarko B. Concentration of latanoprost ophthalmic solution after 4 to 6 weeks\u2019 use in an eye clinic setting. Investig Ophthalmol Vis Sci. 2006;47:222.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3452_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-8-11","volume":"8","author":"MD Paolera","year":"2008","unstructured":"Paolera MD, Kasahara N, Umbelino CC, Walt JG. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. BMC Ophthalmol. 2008;8:11.","journal-title":"BMC Ophthalmol"},{"key":"3452_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00061198-200110000-00007","volume":"10","author":"PV Morgan","year":"2001","unstructured":"Morgan PV, Proniuk S, Blanchard J, Noecker RJ. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma. 2001;10:401\u20135.","journal-title":"J Glaucoma"},{"key":"3452_CR55","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/02713683.2014.939763","volume":"40","author":"T Velpandian","year":"2015","unstructured":"Velpandian T, Kotnala A, Halder N, Ravi AK, Archunan V, Sihota R. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies. Curr Eye Res. 2015;40:561\u201371.","journal-title":"Curr Eye Res"},{"key":"3452_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IIO.0000000000000232","volume":"58","author":"M Banitt","year":"2018","unstructured":"Banitt M, Jung H. Ocular surface disease in the glaucoma patient. Int Ophthalmol Clin. 2018;58:23\u201333.","journal-title":"Int Ophthalmol Clin"},{"key":"3452_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12325-014-0125-9","volume":"31","author":"AGP Konstas","year":"2014","unstructured":"Konstas AGP, Voudouragkaki IC, Boboridis KG, Haidich A-B, Paschalinou E, Giannopoulos T, et al. 24-Hour efficacy of travoprost\/timolol BAK-free versus latanoprost\/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31:592\u2013603.","journal-title":"Adv Ther"},{"key":"3452_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/OPTH.S3881","volume":"2","author":"J Stewart","year":"2008","unstructured":"Stewart J. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613\u20138.","journal-title":"Clin Ophthalmol"},{"key":"3452_CR59","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/OPTH.S367756","volume":"16","author":"B Shen Lee","year":"2022","unstructured":"Shen Lee B, Malhotra R, Sall K, Mitchell B, Peace J. Open-label extension study comparing latanoprost 0.005% without vs. with benzalkonium chloride in open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2022;16:2285\u201393.","journal-title":"Clin Ophthalmol"},{"key":"3452_CR60","doi-asserted-by":"publisher","first-page":"14971","DOI":"10.1038\/s41598-021-94574-x","volume":"11","author":"DW Kim","year":"2021","unstructured":"Kim DW, Shin J, Lee CK, Kim M, Lee S, Rho S. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial. Sci Rep. 2021;11:14971.","journal-title":"Sci Rep"},{"key":"3452_CR61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2024.08.001","volume":"34","author":"MY Kahook","year":"2024","unstructured":"Kahook MY, Rapuano CJ, Messmer EM, Radcliffe NM, Galor A, Baudouin C. Preservatives and ocular surface disease: a review. Ocul Surf. 2024;34:213\u201324.","journal-title":"Ocul Surf"},{"key":"3452_CR62","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMra1407936","volume":"378","author":"JA Clayton","year":"2018","unstructured":"Clayton JA. Dry eye. N Engl J Med. 2018;378:2212\u201323.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03452-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03452-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03452-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:08Z","timestamp":1771268588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03452-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03452-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chara Tsiampali and Chrysanthi Sardeli: no disclosures; Iordanis Vagiakis: travel support from Vianex; Anastasios\u00a0G. Konstas: research funding from Bayer, Omni Vision, Santen and Th\u00e9a; fees for consultancy and lectures with travel support from Esteve, Intermed, Santen, Th\u00e9a and Vianex. Prof. Anastasios\u00a0G. Konstas is an Editorial Board member of Advances in Therapy. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}